Abpro (ABP) Competitors $0.21 +0.02 (+10.47%) As of 10/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ABP vs. NRXP, QNTM, MNOV, CUE, CELU, ALGS, ELYM, ICCC, ACRV, and GNTAShould you be buying Abpro stock or one of its competitors? The main competitors of Abpro include NRx Pharmaceuticals (NRXP), Quantum Biopharma (QNTM), MediciNova (MNOV), Cue Biopharma (CUE), Celularity (CELU), Aligos Therapeutics (ALGS), Eliem Therapeutics (ELYM), ImmuCell (ICCC), Acrivon Therapeutics (ACRV), and Genenta Science (GNTA). These companies are all part of the "pharmaceutical products" industry. Abpro vs. Its Competitors NRx Pharmaceuticals Quantum Biopharma MediciNova Cue Biopharma Celularity Aligos Therapeutics Eliem Therapeutics ImmuCell Acrivon Therapeutics Genenta Science Abpro (NASDAQ:ABP) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation. Does the media refer more to ABP or NRXP? In the previous week, NRx Pharmaceuticals had 3 more articles in the media than Abpro. MarketBeat recorded 5 mentions for NRx Pharmaceuticals and 2 mentions for Abpro. Abpro's average media sentiment score of 0.90 beat NRx Pharmaceuticals' score of 0.86 indicating that Abpro is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abpro 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ABP or NRXP more profitable? Company Net Margins Return on Equity Return on Assets AbproN/A N/A -241.16% NRx Pharmaceuticals N/A N/A -550.94% Which has higher earnings & valuation, ABP or NRXP? Abpro has higher revenue and earnings than NRx Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$180K93.49-$7.23MN/AN/ANRx PharmaceuticalsN/AN/A-$25.13M-$2.24-1.42 Do institutionals and insiders believe in ABP or NRXP? 23.3% of Abpro shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 13.7% of Abpro shares are owned by insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend ABP or NRXP? Abpro presently has a consensus target price of $4.00, indicating a potential upside of 1,805.67%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 988.33%. Given Abpro's higher possible upside, equities research analysts plainly believe Abpro is more favorable than NRx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Which has more volatility and risk, ABP or NRXP? Abpro has a beta of 0.02, indicating that its share price is 98% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.74, indicating that its share price is 74% more volatile than the S&P 500. SummaryAbpro and NRx Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get Abpro News Delivered to You Automatically Sign up to receive the latest news and ratings for ABP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ABP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABP vs. The Competition Export to ExcelMetricAbproMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.23M$3.37B$6.11B$10.46BDividend YieldN/A2.29%5.73%4.77%P/E RatioN/A22.7785.3627.36Price / Sales93.49465.72601.96132.92Price / CashN/A46.7037.4661.86Price / Book-0.7210.5512.426.81Net Income-$7.23M-$52.58M$3.32B$276.80M7 Day Performance6.28%0.09%0.57%0.42%1 Month Performance15.39%15.61%10.52%7.86%1 Year PerformanceN/A15.13%72.99%41.24% Abpro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABPAbpro3.4959 of 5 stars$0.21+10.5%$4.00+1,805.7%N/A$15.23M$180K0.0015News CoverageGap DownNRXPNRx Pharmaceuticals3.2878 of 5 stars$3.16+3.6%$34.50+992.1%+164.2%$62.50MN/A-1.412QNTMQuantum Biopharma0.4239 of 5 stars$15.96-0.2%N/A+215.6%$60.90MN/A-1.14N/AMNOVMediciNova2.9725 of 5 stars$1.24-0.4%$7.00+464.5%-31.5%$60.82M$134.60K-4.9610Analyst ForecastCUECue Biopharma2.6555 of 5 stars$0.79-0.7%N/A-29.9%$60.79M$9.29M-1.4160News CoverageAnalyst ForecastCELUCelularity2.0349 of 5 stars$2.22-2.4%$6.00+170.9%-22.5%$59.79M$54.22M-0.70220ALGSAligos Therapeutics3.8824 of 5 stars$9.79+1.4%$50.00+410.6%+42.8%$59.75M$3.94M-0.4990News CoverageELYMEliem TherapeuticsN/A$2.00+11.1%N/A-65.4%$59.50MN/A-3.779Gap DownICCCImmuCell1.143 of 5 stars$6.42-1.5%N/A+86.8%$58.10M$26.49M33.7970ACRVAcrivon Therapeutics2.5537 of 5 stars$1.85+6.0%$15.00+713.0%-75.1%$57.85MN/A-0.8258GNTAGenenta Science0.9115 of 5 stars$3.11-10.5%N/A-44.8%$56.79MN/A0.007 Related Companies and Tools Related Companies NRXP Alternatives QNTM Alternatives MNOV Alternatives CUE Alternatives CELU Alternatives ALGS Alternatives ELYM Alternatives ICCC Alternatives ACRV Alternatives GNTA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ABP) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredThe Final DisplacementA new documentary called The Final Displacement is stirring major controversy — and for good reason. It expose...Porter & Company | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abpro Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abpro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
